查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1976642

人工植入市场：依植入类型、技术、材质和最终用户划分－2026-2032年全球预测

Artificial Implants Market by Implant Type, Technology, Material Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人工植入市场价值将达到 472.4 亿美元，到 2026 年将成长至 511.6 亿美元，到 2032 年将达到 834.4 亿美元，复合年增长率为 8.46%。

主要市场统计数据
基准年 2025 472.4亿美元
预计年份：2026年 511.6亿美元
预测年份 2032 834.4亿美元
复合年增长率 (%) 8.46%

临床、监管和製造趋势构成了一个策略框架，塑造着植入式医疗设备。

人口压力、技术突破和医疗模式的变革正推动人工植入领域经历持续的结构性变革时期。临床医生越来越多地使用兼具机械功能和生物相容性的植入式装置来治疗慢性病和退化性疾病。相关人员正积极回应，加大对材料科学、积层製造和互联功能的投入。随着医疗机构和患者对能够降低再次手术率、缩短恢復时间和实现远端监测的植入的需求日益增长，产品开发正从单一学科工程转向融合生物材料、软体和外科技术的跨学科项目。

对以患者主导的护理、积层製造技术、智慧设备整合和监管进步如何重塑植入开发进行详细、全面的分析。

近年来，植入领域的进展反映了变革性的改变，重新定义了产品生命週期和医疗服务模式。首先，以患者为中心的照护模式和完善的报销机制，使得人们更加关注对患者至关重要的疗效指标，例如功能性、耐用性和生活品质。因此，能够最大限度地减少併发症并促进更快康復的材料和器械结构，已成为设计重点。其次，积层製造和先进的表面处理技术已从原型製作走向大规模生产，从而能够製造出形状更复杂的植体、植入的患者特异性植体，并增强骨整合性能。第三，数位技术的融合加速了智慧植入的应用，这些植体整合了遥测、感测器和封闭回路型刺激功能。这使得植体的价值不再局限于机械正畸，而是扩展到持续的生理管理。

基于证据评估贸易壁垒上升对采购、製造地策略、定价趋势和供应商风险管理的影响。

美国贸易政策调整引发的关税措施正对全球植入供应链和商业策略产生连锁反应。特定零件和原材料进口关税的提高直接增加了依赖海外供应商的製造商的到岸成本，迫使采购团队重新审视其供应商组合，加快在地采购，或对替代供应商进行认证。为此，一些製造商优先考虑库存缓衝和双重采购策略，以确保手术用品供应的连续性；而另一些製造商则考虑对易受关税波动影响的关键零件进行垂直整合。

将设备分类、医疗环境、材料选择和底层技术与临床要求和商业化途径连结起来的多维分割分析。

详细的細項分析揭示了不同类型植入、最终用户、材料和底层技术如何影响其开发重点和应用模式。在植入分类系统中，其范围涵盖循环系统器械，例如心臟瓣膜、心律调节器、支架和血管移植物。心臟瓣膜进一步细分为生物瓣膜和机械瓣膜，支架则根据其在冠状动脉和周边血管中的应用进行区分。人工电子耳神经刺激设备、整形外科、视网膜和泌尿系统植入各有不同的临床需求。整形外科解决方案进一步分为骨板和螺丝钉、关节重建、脊椎融合手术和创伤固定，其中关节重建包括髋关节、膝关节和肩关节手术。每个类别对耐用性、影像相容性、动态性能和外科医生工作流程都有不同的要求。

区域情报概述：本节阐述了不同的管理体制、支付模式和製造能力如何影响全球市场引进和商业化策略。

区域趋势对产品开发重点、监管策略和商业化计画有显着影响。在美洲，支付模式、医院整合趋势以及完善的临床研究基础设施正在推动对高品质、功能丰富的植入以及支援疗效评估和远端追踪的数位化平台的需求。美国是先进临床试验和下一代技术早期应用的中心，这通常为技术向该地区其他市场的扩散创造了途径。

企业环境评估，解释了现有产品组合、敏捷创新者和策略伙伴关係如何结合起来，加速医疗设备的转换和商业性规模。

植入产业的企业行为体现了在维持现有业务和追求颠覆性创新之间的平衡。成熟的医疗设备製造商倾向于对成熟平台进行渐进式改进，优化生产效率，透过强化涂层和模组化设计延长产品生命週期，并利用现有的应用经验累积证据。同时，新兴企业和专业技术公司则专注于突破性材料、生物可吸收结构、用于特异性患者的积层製造技术，以及能够实现远端监测和封闭回路型治疗的嵌入式数位功能。

为经营团队提供实用指导，透过调整证据产生和供应网路的韧性和技术模组化，确保临床应用和商业性可持续性。

产业领导者应采取积极主动的方式，整合临床证据的建立、供应链韧性和技术差异化。优先考虑模组化产品架构和可互通的软体框架，可实现分阶段更新，而无需更换整个平台。此外，对来自註册登记和连网设备的资料流的投资，有助于履行基于价值的合约和满足上市后监测要求。为降低供应商集中风险，企业应认证关键合金、聚合物和电子子系统的替代供应商，并建立清晰的供应商绩效指标和快速检验流程。

严谨的混合方法研究框架结合了相关人员访谈、监管和技术分析以及检验，检验业界考察和策略指导。

本执行摘要的研究结合了对关键相关人员的访谈、系统的二手资讯回顾以及有针对性的技术分析，旨在建立植入领域的全面而全面的整体情况。主要资讯来源包括与来自不同专科的临床医生、来自不同医疗机构的采购经理、监管事务专业人员以及参与材料和製造的技术专家的对话。这些质性见解辅以对监管指导文件、临床试验註册资讯、专利申请和同行评审文献的系统性回顾，以检验有关安全性、有效性和技术成熟度的说法。

简明扼要地总结道，多学科创新、供应韧性和实证策略决定了植入领域的竞争优势。

人工植入正进入一个关键阶段，跨学科创新、监管监管和稳健的製造系统将决定其成败。尖端材料、积层製造和数位化整合技术的融合，不仅创造出能够恢復功能，还能提供持续临床洞察的植入物，改变了人们对植入的期望。同时，供应链的脆弱性、关税带来的成本压力以及不同地区监管路径的差异，都要求企业采用灵活的采购模式和积极主动的监管策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：人工植入市场（以植入类型划分）

  • 心血管系统
    • 心臟瓣膜
      • 生物瓣膜
      • 机械的
    • 起搏器
    • 支架
      • 冠状动脉
      • 外围
    • 血管移植
  • 人工电子耳
  • 美丽
  • 牙科
  • 神经刺激设备
  • 整形外科
    • 骨板和螺丝
    • 关节重建
      • 髋关节
      • 膝盖
      • 肩膀
    • 脊椎融合手术
    • 创伤固定
  • 视网膜
  • 泌尿系统

第九章：人工植入市场：依技术划分

  • 3D列印
  • 生物活性涂层
  • 药物释放型型
  • 微创
  • 智慧植入

第十章：人工植入市场：依材料类型划分

  • 合金
  • 可生物降解材料
  • 陶瓷
  • 聚合物
  • 钛

第十一章：人工植入市场：依最终用户划分

  • 门诊手术中心
  • 诊所
  • 居家医疗
  • 医院

第十二章 人工植入市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：人工植入市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 人工植入市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国人工植入市场

第十六章：中国人工植入市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Advanced Bionics Corporation by Sonova Holding AG
  • Aesculap Implant Systems by B. Braun Medical, Inc.
  • Bicon, LLC
  • Boston Scientific Corporation
  • Cochlear Limited
  • DENTSPLY SIRONA Inc.
  • DIOPTEX GmbH
  • Exactech Inc.
  • EyeYon
  • FCI Ophthalmics, Inc.
  • GS Solutions, Inc.
  • Johnson & Johnson
  • KeraMed, Inc.
  • Medical Device Business Services, Inc. by Johnson & Johnson
  • Medtronic plc
  • Nobel Biocare Services AG
  • NuVasive, Inc.
  • Smith & Nephew Plc
  • Straumann Holding AG
  • Stryker Corporation
  • Terumo Corporation
  • TTK Healthcare Limited
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-69324464D1A9

The Artificial Implants Market was valued at USD 47.24 billion in 2025 and is projected to grow to USD 51.16 billion in 2026, with a CAGR of 8.46%, reaching USD 83.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.24 billion
Estimated Year [2026] USD 51.16 billion
Forecast Year [2032] USD 83.44 billion
CAGR (%) 8.46%

A strategic framing of clinical, regulatory, and manufacturing dynamics shaping the future of implantable medical devices across disciplines

The landscape of artificial implants is experiencing a period of sustained structural change driven by demographic pressures, technological breakthroughs, and shifting care models. Clinicians increasingly treat chronic and degenerative conditions with implantable devices that blend mechanical function with biological integration, and industry stakeholders are responding by investing in materials science, additive manufacturing, and connected-device capabilities. As institutions and patients demand implants that reduce revision rates, shorten recovery times, and enable remote monitoring, product development has shifted away from single-discipline engineering toward multidisciplinary programs that combine biomaterials, software, and surgical technique.

Parallel to clinical advances, regulatory agencies have updated guidance to reflect novel device pathways and greater emphasis on post-market surveillance, which together inform design, testing, and commercial strategies. Supply chain dynamics, including sourcing of specialty alloys, polymer formulations, and precision components, are increasingly relevant to manufacturers' ability to deliver consistent quality at scale. In this context, stakeholders from hospital systems to device startups must navigate an environment where clinical evidence, manufacturing robustness, and digital integration determine long-term adoption. This executive summary synthesizes these interdependent forces to provide leaders with a concise, evidence-based view of the trends shaping innovation and market behavior across implant types, end users, materials, technologies, regions, and corporate actors.

A detailed synthesis of patient-driven care, additive manufacturing, smart device integration, and regulatory evolution reshaping implant development

The evolution of the implant sector in recent years reflects transformative shifts that are redefining product lifecycles and care delivery. First, patient-centric care models and bundled reimbursement frameworks have increased focus on outcomes that matter to patients, such as functionality, longevity, and quality of life; consequently, design priorities have moved toward materials and device architectures that minimize complications and support faster rehabilitation. Second, additive manufacturing and sophisticated surface engineering techniques have transitioned from prototyping tools to production-ready methods, enabling more complex geometries, patient-specific implants, and enhanced osseointegration properties. Third, digital convergence has accelerated the deployment of smart implants that incorporate telemetry, sensors, or closed-loop stimulation, thereby extending device value beyond mechanical correction to continuous physiologic management.

Regulatory and clinical evidence expectations have also changed, emphasizing real-world data collection and life-cycle risk management. As a result, manufacturers are investing in registries, remote monitoring platforms, and adaptive trial designs. Meanwhile, materials innovation - including bioactive coatings, resorbable polymers, and hybrid composites - is unlocking new therapeutic possibilities while challenging legacy manufacturing processes. Finally, strategic partnerships among device firms, contract manufacturers, and health systems are becoming more prevalent, as each seeks to de-risk development, expand clinical access, and accelerate time-to-implant. Taken together, these shifts are creating an environment where agility, cross-disciplinary expertise, and robust post-market intelligence determine competitive advantage.

An evidence-based appraisal of how elevated trade barriers are influencing procurement, manufacturing location strategy, pricing dynamics, and supplier risk management

Tariff actions originating from trade policy adjustments in the United States have collateral effects across global implant supply chains and commercial strategies. Increased import duties on select components or raw materials directly raise landed costs for manufacturers reliant on overseas suppliers, prompting procurement teams to revisit supplier portfolios and to accelerate local sourcing or qualification of alternate vendors. In response, some manufacturers prioritize inventory buffers and dual sourcing strategies to maintain surgical supply continuity, while others explore vertical integration for critical components that are sensitive to tariff volatility.

Beyond immediate cost implications, tariffs influence longer-term strategic decisions about plant location, contract manufacturing relationships, and capital allocation. For example, manufacturers evaluating capacity expansion may factor in tariff-related operating cost differentials when assessing nearshoring versus maintaining low-cost offshore production. Tariffs can also alter product pricing dynamics in healthcare systems that already face constrained reimbursement, potentially shifting negotiations between manufacturers and providers and accelerating demand for lower-cost alternative technologies. Additionally, regulatory approval timelines and conformity assessments for components sourced from new suppliers require careful management to avoid implant availability disruptions.

Importantly, tariffs interact with non-tariff trade measures and export controls, amplifying complexity for companies operating across multiple jurisdictions. Therefore, companies must consider both macroeconomic trade policy trends and granular supplier risk when planning production and commercialization, balancing cost mitigation with the need to preserve quality, clinical performance, and regulatory compliance.

A multidimensional segmentation analysis linking device classes, care settings, material choices, and enabling technologies to clinical requirements and commercialization pathways

A granular segmentation lens reveals how development priorities and adoption patterns diverge across implant types, end users, materials, and enabling technologies. When viewed through implant taxonomy, the universe spans cardiovascular devices such as heart valves, pacemakers, stents, and vascular grafts, with heart valves subdivided by bioprosthetic and mechanical designs and stents differentiated into coronary and peripheral indications. Cochlear, cosmetic, dental, neurostimulator, orthopedic, retinal, and urological implants present distinct clinical requirements, while orthopedic solutions further divide into bone plates and screws, joint replacement, spinal fusion, and trauma fixation, with joint replacement encompassing hip, knee, and shoulder procedures. Each category imposes different demands on durability, imaging compatibility, biomechanical performance, and surgeon workflow.

End-user segmentation highlights divergent procurement and care pathways, from ambulatory surgical centers and clinics to home care environments and hospitals. These settings vary in procedural volume, capital equipment availability, and decision-making timelines, which in turn affect product design, packaging, and support services. Material selection likewise differentiates product strategies; alloys continue to underpin load-bearing implants, biodegradable materials enable transient scaffolds and drug delivery applications, ceramics offer wear resistance in articulating surfaces, polymers provide design flexibility and radiolucency, and titanium remains the standard for many load-bearing orthopaedic and craniofacial indications. Technology segmentation illuminates the impact of additive manufacturing for patient-specific geometries, bioactive coatings for surface integration, drug-eluting platforms for infection or restenosis control, minimally invasive approaches that reduce tissue trauma, and smart implants that deliver sensing or therapy modulation. Integrating these segmentation dimensions allows stakeholders to prioritize R&D investments, tailor regulatory strategies, and align commercialization plans with the clinical environments that will ultimately use and support the implants.

A regional intelligence overview explaining how distinct regulatory regimes, payer models, and manufacturing capabilities shape adoption and commercialization strategies across global markets

Regional dynamics significantly influence product development priorities, regulatory strategy, and commercialization planning. In the Americas, payer models, hospital consolidation trends, and a strong clinical research infrastructure shape demand for high-evidence, feature-rich implants and for digital platforms that support outcomes measurement and remote follow-up. The United States serves as a hub for advanced clinical trials and early adoption of next-generation technologies, which often creates a technology diffusion pathway to other markets in the hemisphere.

In the Europe, Middle East & Africa region, heterogeneity in reimbursement frameworks and regulatory harmonization efforts produce a complex environment for market entry. European regulatory modernization and an emphasis on clinical equivalence or added-value demonstrate the importance of robust post-market data and health-economics evidence. Markets in the Middle East and Africa present pockets of rapid infrastructure investment alongside access challenges, making tiered product strategies and local partnerships valuable for adoption.

The Asia-Pacific region presents a mix of high-volume surgical markets, rapid adoption of cost-effective innovations, and emergent centers of manufacturing and R&D excellence. Diverse regulatory maturation across countries requires nuanced entry strategies, while growing domestic capabilities in materials and additive manufacturing present opportunities for regional supply chain optimization. Across all regions, demographic trends, surgical capacity expansion, and digital health integration drive both common and region-specific priorities for implant developers and their commercial partners.

A corporate landscape appraisal describing how incumbent portfolios, nimble innovators, and strategic partnerships are combining to accelerate device translation and commercial scale-up

Corporate behavior in the implant sector reflects a balancing act between sustaining legacy franchises and pursuing disruptive innovation. Established device manufacturers often focus on incremental improvement to proven platforms, optimizing manufacturing efficiency, extending device lifecycles through enhanced coatings or modularity, and leveraging installed bases for evidence generation. At the same time, emerging companies and specialized technology firms concentrate on breakthrough materials, bioresorbable constructs, additive manufacturing for patient-specific devices, and embedded digital functionality that enables remote monitoring or closed-loop therapies.

Across the competitive landscape, collaboration between original equipment manufacturers, contract development and manufacturing organizations, clinical research networks, and technology providers accelerates translation from concept to clinic. Strategic alliances frequently encompass co-development agreements, licensing of intellectual property, and distribution partnerships that expand geographic reach. Investment trends indicate sustained interest from corporate venture groups and strategic investors in early-stage technologies that promise differentiation through clinical performance or cost-efficiency. In parallel, the role of contract manufacturers and precision component suppliers has become more prominent as companies seek to scale complex production processes while maintaining regulatory compliance and traceability. Taken together, these dynamics underscore the need for a coherent corporate strategy that aligns R&D priorities, manufacturing capabilities, and go-to-market execution to capture long-term value.

Action-oriented guidance for executives to align evidence generation, supply resilience, and technology modularity to secure clinical adoption and commercial durability

Industry leaders should adopt a proactive posture that aligns clinical evidence generation, supply chain resilience, and technology differentiation. Prioritizing modular product architectures and interoperable software frameworks enables incremental updates without full platform replacement, and investing in registries and connected-device data streams supports value-based contracting and post-market surveillance requirements. To mitigate supplier concentration risk, companies should qualify alternate sources for critical alloys, polymers, and electronic subsystems while developing clear supplier performance metrics and expedited validation pathways.

In R&D, integrating materials science with computational modeling and additive manufacturing can shorten design cycles and enable patient-specific solutions that reduce revision rates. Commercial teams should tailor go-to-market strategies to the procedural setting, recognizing that hospitals, ambulatory surgical centers, clinics, and home care pathways have distinct purchasing drivers and post-procedural support needs. Regulatory engagement must begin early and continue throughout product life cycles, emphasizing human factors, durability testing, and real-world performance data to streamline approvals and reimbursement discussions. Finally, leaders should evaluate strategic partnerships and M&A as levers to access complementary capabilities, accelerate market entry, or secure manufacturing capacity, ensuring that cultural and operational integration plans are developed to capture intended synergies.

A rigorous mixed-methods research framework combining stakeholder interviews, regulatory and technical analysis, and triangulation to validate sector insights and strategic guidance

The research underpinning this executive summary combines primary stakeholder interviews, systematic secondary-source review, and targeted technical analysis to create a robust picture of the implant sector. Primary inputs included conversations with clinicians across specialties, procurement leaders from diverse care settings, regulatory affairs professionals, and technology experts involved in materials and manufacturing. These qualitative insights were complemented by a structured review of regulatory guidance documents, clinical trial registries, patent filings, and peer-reviewed literature to validate claims around safety, efficacy, and technological readiness.

Technical assessment incorporated materials characterization literature, manufacturing case studies, and analysis of device architectures to identify trends in additive manufacturing, coatings, and embedded electronics. Supply chain analysis leveraged trade flow data and public procurement documentation to assess sourcing risks and potential tariff impacts. Where applicable, scenario-based analysis was used to explore how changes in policy, reimbursement, or manufacturing cost profiles might affect strategic choices. Throughout the research process, findings were triangulated across multiple sources to mitigate bias, and expert review panels provided challenge and validation to key conclusions and recommendations.

A concise closing synthesis underscoring how multidisciplinary innovation, supply resilience, and evidence strategies will determine competitive positioning in the implant sector

Artificial implants are entering a phase where multidisciplinary innovation, regulatory vigilance, and resilient manufacturing will determine success. The interplay between advanced materials, additive manufacturing, and digital integration is creating devices that not only restore function but also provide continuous clinical insight, shifting expectations for what implants can deliver. At the same time, supply chain fragility, tariff-induced cost pressures, and divergent regional regulatory pathways require companies to adopt flexible sourcing models and proactive regulatory strategies.

Strategically, organizations that invest in evidence generation, design for manufacturability, and interoperable digital ecosystems will be better positioned to meet clinicians' and patients' evolving expectations. Collaboration across the value chain-from raw material suppliers to health systems-will be essential to accelerate safe deployment and to demonstrate value in real-world settings. In conclusion, the implant sector's near-term trajectory rewards those who combine technical excellence with operational discipline and clear clinical partnerships to drive sustainable adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Implants Market, by Implant Type

  • 8.1. Cardiovascular
    • 8.1.1. Heart Valves
      • 8.1.1.1. Bioprosthetic
      • 8.1.1.2. Mechanical
    • 8.1.2. Pacemakers
    • 8.1.3. Stents
      • 8.1.3.1. Coronary
      • 8.1.3.2. Peripheral
    • 8.1.4. Vascular Grafts
  • 8.2. Cochlear
  • 8.3. Cosmetic
  • 8.4. Dental
  • 8.5. Neurostimulators
  • 8.6. Orthopedic
    • 8.6.1. Bone Plates & Screws
    • 8.6.2. Joint Replacement
      • 8.6.2.1. Hip
      • 8.6.2.2. Knee
      • 8.6.2.3. Shoulder
    • 8.6.3. Spinal Fusion
    • 8.6.4. Trauma Fixation
  • 8.7. Retinal
  • 8.8. Urological

9. Artificial Implants Market, by Technology

  • 9.1. 3D Printing
  • 9.2. Bioactive Coatings
  • 9.3. Drug-Eluting
  • 9.4. Minimally Invasive
  • 9.5. Smart Implants

10. Artificial Implants Market, by Material Type

  • 10.1. Alloys
  • 10.2. Biodegradable Materials
  • 10.3. Ceramics
  • 10.4. Polymers
  • 10.5. Titanium

11. Artificial Implants Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Home Care
  • 11.4. Hospitals

12. Artificial Implants Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Artificial Implants Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Artificial Implants Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Artificial Implants Market

16. China Artificial Implants Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Advanced Bionics Corporation by Sonova Holding AG
  • 17.7. Aesculap Implant Systems by B. Braun Medical, Inc.
  • 17.8. Bicon, LLC
  • 17.9. Boston Scientific Corporation
  • 17.10. Cochlear Limited
  • 17.11. DENTSPLY SIRONA Inc.
  • 17.12. DIOPTEX GmbH
  • 17.13. Exactech Inc.
  • 17.14. EyeYon
  • 17.15. FCI Ophthalmics, Inc.
  • 17.16. GS Solutions, Inc.
  • 17.17. Johnson & Johnson
  • 17.18. KeraMed, Inc.
  • 17.19. Medical Device Business Services, Inc. by Johnson & Johnson
  • 17.20. Medtronic plc
  • 17.21. Nobel Biocare Services AG
  • 17.22. NuVasive, Inc.
  • 17.23. Smith & Nephew Plc
  • 17.24. Straumann Holding AG
  • 17.25. Stryker Corporation
  • 17.26. Terumo Corporation
  • 17.27. TTK Healthcare Limited
  • 17.28. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL IMPLANTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL IMPLANTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOPROSTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOPROSTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOPROSTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PACEMAKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PACEMAKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PACEMAKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COCHLEAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COCHLEAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COCHLEAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COSMETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COSMETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COSMETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY NEUROSTIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY NEUROSTIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY NEUROSTIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BONE PLATES & SCREWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BONE PLATES & SCREWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BONE PLATES & SCREWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY KNEE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY KNEE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SHOULDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SPINAL FUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SPINAL FUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SPINAL FUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY RETINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY RETINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY RETINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY UROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY UROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY 3D PRINTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY 3D PRINTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY 3D PRINTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOACTIVE COATINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOACTIVE COATINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOACTIVE COATINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DRUG-ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DRUG-ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DRUG-ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SMART IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SMART IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SMART IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ALLOYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ALLOYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ALLOYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIODEGRADABLE MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIODEGRADABLE MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIODEGRADABLE MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CERAMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CERAMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CERAMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TITANIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TITANIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TITANIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)